SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR), a developer of medical devices for the treatment of neurological diseases and disorders, today announced promising initial data from an eight patient investigational device feasibility study (SAHALE) of cortical stimulation to treat tinnitus. The study’s principal investigators, Brian Kopell, M.D. of the Medical College of Wisconsin’s Department of Neurosurgery and David Friedland, M.D., Ph.D. of the Medical College of Wisconsin’s Department of Otolaryngology, found that investigational cortical stimulation of the auditory cortex for the suppression of tinnitus is feasible and appears to be safe. These findings were presented by Dr. Friedland this past weekend at the annual meeting of the American Neurotology Society in San Diego.
